头颈癌患者数据收集、放疗及生存的院际差异:一项多中心研究
该多中心研究基于澳大利亚七家医院2000—2017年3182例接受根治性放疗的原发性非转移性头颈鳞癌成人患者数据,发现数据收集完整度、原发放疗剂量和五年头颈癌相关死亡存在院际差异。较高的EQD2T剂量与五年头颈癌相关死亡风险降低相关,医院、肿瘤部位及T和N分期为独立预后因素。
要点
- 七家澳大利亚医院3182例头颈鳞癌患者中,11个字段的完成率为66%—98%,存在院际差异。
- Tis-T1N0声门癌及任何分期口腔癌和口咽癌的原发放疗EQD2T剂量因医院而异,观察到偏离澳大利亚放疗指南。
- 较高EQD2T剂量与全部患者及原发放疗患者五年头颈癌相关死亡风险降低相关。
核心结论
- 在澳大利亚医院接受治疗的头颈癌患者中,头颈癌相关死亡存在无法解释的院际差异。
- 肿瘤信息系统(OIS)中可获得的常规收集数据不足以解释生存差异。
- 需要创新的数据收集、提取和分类实践来为临床实践提供信息。
研究设计与样本
- 多中心研究,从七家澳大利亚医院的肿瘤信息系统(OIS)中提取2000—2017年3182例接受根治性放疗(伴或不伴手术或化疗)的原发性非转移性头颈鳞癌成人患者数据。
- 死亡数据通过记录链接从国家死亡索引获取,采用多变量Cox回归评估生存与医院的关联。
主要发现
- 检测到数据收集、原发放疗剂量和五年头颈癌相关死亡存在院际差异。
- 11个字段的完成率范围为66%—98%。
- 接受原发放疗的Tis-T1N0声门癌及任何分期口腔癌和口咽癌患者的EQD2T剂量因医院而显著不同,观察到偏离澳大利亚放疗指南。
- 较高的EQD2T剂量与全部患者及接受原发放疗患者五年头颈癌相关死亡风险降低相关。
- 医院、肿瘤部位以及T和N分期被确定为全部接受放疗患者五年头颈癌相关死亡的独立预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Inter-hospital inequalities in head and neck cancer (HNC) survival may exist due to variation in radiotherapy treatment-related factors. This study investigated inter-hospital variation in data collection, primary radiotherapy treatment, and survival in HNC patients from an Australian setting. MATERIALS AND METHODS: Data collected in oncology information systems (OIS) from seven Australian hospitals was extracted for 3,182 adults treated with curative radiotherapy, with or without surgery or chemotherapy, for primary, non-metastatic squamous cell carcinoma of the head and neck (2000-2017). Death data was sourced from the National Death Index using record linkage. Multivariable Cox regression was used to assess the association between survival and hospital. RESULTS: Inter-hospital variation in data collection, primary radiotherapy dose, and five-year HNC-related death was detected. Completion of eleven fields ranged from 66%-98%. Primary radiotherapy treated Tis-T1N0 glottic and any stage oral cavity and oropharynx cancers received significantly different time-corrected biologically equivalent dose in two gray fractions (EQD2T) by hospital, with observed deviation from Australian radiotherapy guidelines. Increased EQD2T dose was associated with a reduced risk of five-year HNC-related death in all patients and those treated with primary radiotherapy. Hospital, tumour site, and T and N classification were also identified as independent prognostic factors for five-year HNC-related death in all patients treated with radiotherapy. CONCLUSION: Unexplained variation exists in HNC-related death in patients treated at Australian hospitals. Available routinely collected data in OIS are insufficient to explain variation in survival. Innovative data collection, extraction, and classification practices are needed to inform clinical practice.
引用
- Kotevski DP, Vajdic CM, Field M, et al. Inter-hospital variation in data collection, radiotherapy treatment, and survival in patients with head and neck cancer: A multisite study. Radiother Oncol. 2023. PMID: 37543056. doi:10.1016/j.radonc.2023.109843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。